Dishman Carbogen Amcis Limited

NSEI:DCAL Stock Report

Market Cap: ₹38.7b

Dishman Carbogen Amcis Valuation

Is DCAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DCAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DCAL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DCAL's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DCAL?

Key metric: As DCAL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DCAL. This is calculated by dividing DCAL's market cap by their current revenue.
What is DCAL's PS Ratio?
PS Ratio1.5x
Sales₹26.19b
Market Cap₹38.68b

Price to Sales Ratio vs Peers

How does DCAL's PS Ratio compare to its peers?

The above table shows the PS ratio for DCAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
INNOVACAP Innova Captab
5.3x26.4%₹62.6b
TARSONS Tarsons Products
6.6x14.5%₹23.2b
524394 Vimta Labs
6.1xn/a₹20.6b
WINDLAS Windlas Biotech
3.3xn/a₹23.1b
DCAL Dishman Carbogen Amcis
1.5xn/a₹38.7b

Price-To-Sales vs Peers: DCAL is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (5.3x).


Price to Sales Ratio vs Industry

How does DCAL's PS Ratio compare vs other companies in the Asian Life Sciences Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
DCAL 1.5xIndustry Avg. 4.4xNo. of Companies12PS02.85.68.411.214+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DCAL is good value based on its Price-To-Sales Ratio (1.5x) compared to the Asian Life Sciences industry average (4.4x).


Price to Sales Ratio vs Fair Ratio

What is DCAL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DCAL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DCAL's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies